1. Patel, A, Agarwal, R, Rudramurthy, SM, et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerg Infect Dis 2021; 27(9): 2349–2359.
Google Scholar | Crossref | Medline2. Rudramurthy, SM, Hoenigl, M, Meis, JF, et al. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses 2021; 64(9): 1028–1037.
Google Scholar | Crossref | Medline3. Prakash, H, Chakrabarti, A. Global epidemiology of mucormycosis. J Fungi (Basel) 2019; 5(1): 26.
Google Scholar | Crossref4. Petrikkos, G, Skiada, A, Lortholary, O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54(Suppl 1): S23–S34.
Google Scholar | Crossref | Medline | ISI5. Singh, AK, Singh, R, Joshi, SR, et al. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021; 15(4): 102146.
Google Scholar | Crossref | Medline6. Revannavar, SM, Supriya, PS, Samaga, L, et al. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ Case Rep 2021; 14(4): e241663.
Google Scholar | Crossref | Medline7. Chamilos, G, Lewis, RE, Kontoyiannis, DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47(4): 503–509.
Google Scholar | Crossref | Medline8. Wolthers, MS, Schmidt, G, Gjørup, CA, et al. Surgical management of rhinocerebral mucormycosis: a case series. JPRAS Open 2021; 30: 33–37.
Google Scholar | Crossref | Medline